Dostarlimab for advanced endometrial cancer in India
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a drug called dostarlimab for people in India whose endometrial cancer has come back or spread and has a specific genetic profile (dMMR/MSI-H). It may be an option if platinum-based chemotherapy stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Your endometrial cancer has a specific genetic change called dMMR/MSI-H
- Your cancer came back or spread and got worse after treatment with platinum chemo
- Women who can have children must use birth control during treatment and for 4 months after
- You must not have had previous treatment with certain immunotherapy drugs (anti-PD-1 or anti-PD-L1)
- No serious liver or kidney disease or uncontrolled infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the safety of the drug dostarlimab for people with advanced or recurrent endometrial cancer that has come back after initial treatment. It is for adults in India whose cancer cannot be cured by surgery or radiation alone.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a new maintenance treatment (GSK5733584) for women with a certain type of endometrial cancer (MMRp or MSS). It's for people whose cancer has not grown after initial chemo and immunotherapy, and they will continue immunotherapy as part of the study.
This trial tests the drug dostarlimab, alone or with other therapies, given before surgery in people with advanced stage 3 or 4 endometrial cancer. The goal is to see if these treatments shrink the cancer and improve outcomes before the planned operation.
This trial tests a drug called dostarlimab (an immunotherapy) given before surgery for early-stage endometrial cancer that has a specific genetic feature (MMRd/MSI-H). The goal is to see if the drug can shrink or eliminate the cancer before standard surgery.
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
Hear when a new Neoplasms, Endometrial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.